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http://www.biomedcentral.com/1471-2407/12/403RESEARCH ARTICLE Open AccessAnalysis of and prognostic information from
disseminated tumour cells in bone marrow in
primary breast cancer: a prospective
observational study
Anna-Karin Falck1,2, Pär-Ola Bendahl3, Christian Ingvar1,4, Jorma Isola5, Per-Ebbe Jönsson2, Pia Lindblom1,4,
Kristina Lövgren3, Karin Rennstam3, Mårten Fernö3 and Lisa Rydén1,4*Abstract
Background: Disseminated tumour cells (DTCs) in the bone marrow of patients with breast cancer have been
identified as an independent predictor of poor prognosis in patients with non-metastatic disease. This prospective
study aimed to evaluate the presence and prognostic value of DTCs in the bone marrow of female patients with
primary breast cancer.
Methods: Between 1999 and 2003, bone marrow aspirates were obtained from patients at the time of surgery for
primary invasive breast cancer. DTCs in bone marrow were identified using monoclonal antibodies against
cytokeratins for detection of epithelial cells. The detection of DTCs was related to clinical follow-up with distant
disease-free survival (DDFS) and breast cancer-specific survival as endpoints. Bone marrow aspirates from adult
healthy bone marrow donors were analysed separately.
Results: DTCs were analysed in 401 patients, and cytokeratin-positive cells were found in 152 of these (38%). An
immunofluorescence (IF) staining procedure was used in 327 patients, and immunocytochemistry (IC) was
performed in 74 patients. The IF-based method resulted in 40% DTC-positive cases, whereas 30% were positive
using IC (p = 0.11). The presence of DTCs in bone marrow was not significantly related to patient or tumour
characteristics. The presence of DTCs was not a prognostic factor for DDFS (IF: hazards ratio [HR], 2.2; 95%
confidence interval [CI], 0.63–2.2; p = 0.60; IC: HR, 0.84; 95% CI, 0.09–8.1; p = 0.88). Significant prognostic factors were
lymph node metastases, oestrogen receptor positivity, Nottingham histological grade, and tumour size using Cox
univariate analysis. The analyses were positive for epithelial cells in bone marrow from adult healthy donors in 19
(25%) samples.
Conclusions: The detection of DTCs in bone marrow in primary breast cancer was previously shown to be a
predictor of poor prognosis. We were not able to confirm these results in a prospective cohort including
unselected patients before the standard procedure was established. Future studies with a standardised patient
protocol and improved technique for isolating and detecting DTCs may reveal the clinical applications of DTC
detection in patients with micrometastases in the bone marrow.
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Breast cancer remains the most common cancer diagno-
sis among women in Sweden today, with an incidence of
7400 patients per year. It is generally associated with a
good prognosis; more than 85% of Swedish patients are
free from recurrence of the disease at the 5-year follow-
up because of early detection combined with extended
adjuvant therapy [1].
Adjuvant treatment is delivered to eradicate microme-
tastatic spread at the time of diagnosis and thus minim-
ise the risk of subsequent clinically overt metastasis
from the micrometastatic stage. Adjuvant treatment is
tailored to a prognostic profile including validated prog-
nostic factors (age, nodal status, tumour size, Notting-
ham histological grade [NHG], and human epidermal
growth factor receptor 2 [HER2] amplification) and pre-
dictive factors (hormone receptor status, HER2) [2].
Metastatic lymph node involvement (N+) is still consid-
ered to have the strongest impact of all accepted prog-
nostic factors. However, approximately 30% of patients
with no sign of metastatic involvement of the lymph
nodes (N0) relapse and suffer from metastatic disease
[3,4]. In contrast, 40% of N+ patients survive 10 years or
more without recurrence [5,6]. The heterogeneity of
breast cancer challenges the search for further prognos-
tic markers that will provide a more direct measure of
the disease’s metastatic potential. Recognition and
understanding of the metastatic process includes investi-
gation of the molecular mechanism of early spread of
tumour cells.
Micrometastatic spread to bone marrow by disseminated
tumour cells (DTCs), defined as cytokeratin (CK)-positive
cells, occurs in up to 40% of patients with primary breast
cancer at the time of diagnosis [7-10]. DTCs seem to be
unrelated to lymphatic spread and occur in both N0 and
N+disease [7-9], and no distinct pattern is found in rela-
tion to standard prognostic factors [8,9,11,12]. The prog-
nostic influence of DTCs in bone marrow has been
evaluated by several groups over the last 30 years with the
aim of finding a tool to detect micrometastatic disease at
the time of diagnosis [10,13,14]. There has been an in-
creasing acceptance of DTCs as an independent marker of
a poor prognosis in breast cancer after the publication of a
pooled analysis [7], and DTCs are now included in the
new American Joint Committee on Cancer classification as
a diagnostic criteria for micrometastatic spread. Early de-
tection of these epithelial cells may help to identify patients
with micrometastatic disease who would benefit from adju-
vant treatment to prevent further metastatic disease. How-
ever, aspiration and analysis of bone marrow for detection
of DTCs as a prognostic tool is not yet a routine clinical
procedure [15] and is not recommended by the American
Society of Clinical Oncology [16]. Aspiration may be asso-
ciated with pain and discomfort for the patient, particularlyif performed repeatedly to monitor treatment. Further-
more, the increasing acceptance of DTCs as a prognostic
factor is based on studies using different CKs as well as
membrane antibodies to detect epithelial cells [7,15]. Com-
parisons among different detection methods were per-
formed [17] before standardised guidelines were published
[15]. These comparisons showed difficulties in interpreting
CK-positive cells as tumour cells and recommended the
use of markers that allow discrimination between CK-
positive cells of haematopoietic and non-haematopoietic
origin. To ensure validation of the method used, it is im-
portant to have tumour cell samples as positive controls,
specific negative controls, and bone marrow samples from
healthy individuals. Results from clinical studies will vary
until the technique has been standardised and the optimal
dilution with antibodies has been identified.
The aim of the present study was to detect the pres-
ence of DTCs and analyse the prognostic implications of
DTCs in bone marrow at the time of diagnosis in a pro-
spective cohort of patients with primary breast cancer.
An additional aim was to further stratify the cohort
according to lymph node status to enable the clinical in-
formation obtained in N+ and N0 patients to be studied
separately.
Methods
Patients
This study included patients (median age, 58 years) diag-
nosed with primary breast cancer in the South Swedish
Health Care Region between June 1999 and May 2003
as well as patients diagnosed in Lund, Landskrona and
Helsingborg. The patients underwent bone marrow aspir-
ation from the sternal crest under anaesthesia at the time
of primary surgery. The study was approved by the ethics
committee at Lund University, and written informed con-
sent was obtained from all included patients (LU699-09,
LU75-02).
Patient and tumour characteristics are given in Table 1.
Patients underwent either mastectomy or breast-
conserving therapy based on preoperatively identified
characteristics and staging. A sentinel node biopsy was
performed in patients with no sign of axillary node
engagement before surgery, followed by axillary lymph
node dissection (level I and II) at the time of either the
primary operation or a second operation if histopatho-
logical analysis showed metastatic involvement in the
sentinel node biopsy. If node involvement was known
preoperatively, axillary lymph node dissection was
performed at the time of the primary surgery.
Adjuvant therapy was recommended according to
clinical standards following Regional Guidelines, and
included chemotherapy for N+premenopausal women and
N+postmenopausal women with oestrogen receptor-
negative tumours (ER-) (n=65, 16%). Endocrine therapy
Table 1 Patient- and tumor characteristics
Characteristics No of patients (%)
All patients 401 (100)
Age
Median (range) 58 (29–91)
< 50 years 80 (20)
≥ 50 years 321 (80)
Mode of detection
Screening detected 167 (42)
Clinical signs 232 (58)
Unknown 2
Tumor size
≤ 20mm 263 (66)
> 20mm 136 (34)
Unknown 2
Node status
N0 233 (60)
N+ 157 (40)
Unknown 11
NHG
1 77 (20)
2 221 (56)
3 94 (24)
Unknown 9
ER status
Positive 312 (80)
Negative 77 (20)
Unknown 12
PR status
Positive 242 (62)
Negative 147 (38)
Unknown 12
Surgery breast
Mastectomy 157 (39)
Breast concerving surgery 243 (61)
Unknown 1
Surgery axilla
Axillary dissection 247 (63)
Sentinel node biopsy 142 (37)
No Surgery (incl in clinical trial) 12
Adjuvant treatment
No adjuvant treatment 137 (34)
Only Chemotherapy 65 (16)
Only Endocrine therapy 197 (49)
Missing 2
Table 1 Patient- and tumor characteristics (Continued)
Radiotherapy
Breast 198 (49)
Locoregional lymph nodes 35 (9)
Breast + locoregional 39 (10)
Abbreviations: N0= node negative, N+= node positive, NHG= Nottingham
histological grade, ER= oestrogen receptor, PR= progesterone receptor.
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patients with oestrogen receptor-positive (ER+) tumours
and no nodal engagement received tamoxifen, and postme-
nopausal women with ER+ tumours received tamoxifen or
aromatase inhibitors regardless of nodal status. Chemoen-
docrine therapy was given to 22 patients; 137 patients had
no adjuvant therapy. Radiotherapy to the breast was given
after breast-conserving surgery (50 Gy) (n=198, 49%) and
locoregional radiotherapy was delivered if four or more ax-
illary lymph nodes were metastatic (n=35, 9%). A combin-
ation of radiotherapy to the breast and to the locoregional
lymph nodes was delivered in 39 patients (10%).
The patients were followed by annual clinical examin-
ation and mammography. Further clinical and radio-
logical examinations were performed when clinical signs
indicated recurrence of the disease. After 5 years of fol-
low-up, all clinical and histopathological results concern-
ing tumour grading and staging, as well as reports of
events, were abstracted from individual patient’s charts.
The median follow-up for patients without any breast
cancer-related event was 61 months. For patients for
whom no cause of death was registered, we received in-
formation from the Swedish Register of Causes of Death
(Central Statistics Office). The inclusion criteria were re-
evaluated.
The original cohort included 569 patients, 544 of
whom were followed according to the schedule. The
exclusion criteria were no standardised surgical treat-
ment (laser, n = 1), neoadjuvant treatment (n = 11), and
local recurrence (n = 3) and the sample volume was in-
adequate in 36 patients. The analysis was not performed
in 117 patients due to change in research strategy at our
laboratory. The final cohort thus included 401 patients.Bone marrow
Bone marrow aspirates were obtained from the sternum
at two sites by needle aspiration while the patient was
under general anaesthesia at the time of primary surgery.
The samples were transported to the research laboratory
at room temperature and prepared within 1 h. Mono-
nuclear cells were separated by Ficoll density gradient
centrifugation (Ficoll-Paque™ PLUS, Cat. no. 17-1440-03;
Amersham Biosciences AB, Uppsala, Sweden) and then
washed and counted before 1.5 to 2.0 × 106 cells were
Figure 1 Cytokeratin staining of DTCs isolated from bone
marrow by immunofluorescence.
Figure 2 Cytokeratin staining of DTCs isolated from bone
marrow by immunocytochemistry.
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prepared for each patient, one from each site at the
sternum.
Immunofluorescence and immunocytochemical
analysis
In 327 patients, an immunofluorescence (IF) staining pro-
cedure was used for detection of DTCs, including staining
with antibodies against CKs (Pan-CK Ab-2; Neomarkers,
Union City, CA, USA) 4, 5, 6, 7, 8, 10, 13, 14, 15, 16, 18,
and 19 and visualised by IF using an IF microscope
(Axioplan 2; Zeiss, Jena, Germany). The cytospins were
incubated with the pan-CK antibody and a secondary
fluorescein isothiocyanate-conjugated goat antimouse
antibody (Zymed Laboratories Inc., San Francisco, CA,
USA) and finally counterstained with 4,6-diamidino-2-
phenylindol in mounting media using Vectashield (Vector
Laboratories, Burlingame, CA, USA). The procedure
changed when a new CK antibody kit (AE1/AE3; Daco,
Glostrup, Denmark) was introduced with antibodies
against CKs 1, 2, 3, 4, 5, 6, 7, 8, 10, 13, 14, 15, 16, and 19.
For the IC method, the cells were fixed in buffered
formaldehyde (4%) and thereafter pre-treated in citrate
buffer (pH 6) in a microwave oven for 20 minutes.
The cytokeratin antibody kit (AE1/AE3, Daco, Glostrup,
Denmark) was used as primary antibodies against
CK1,2,3,4,5,6,7,8,10,13,14,15,16 and 19. The EnVision™
(Dako, Glostrup, Denmark) was used as detection system,
NovaRed™ (Vector Laboratories, Immunkemi AB, Sollen-
tuna Sweden) for the visualisation and Mayers
hematoxylin for nuclear staining. This enables direct
immunocytochemical evaluation (IC) of the cells and ana-
lysis by light microscope (Olympus CX41, Tokyo, Japan)
in 74 patients.
The presence of DTCs was defined as CK-positive cells
with DTC morphology (irregular staining of the cyto-
plasm) with an enlarged nucleus, irregularity of the nu-
cleus, a high nuclear-to-cytoplasmic ratio, CK staining of
the cytoplasm at the periphery of the cell causing a ring-
like appearance, and fluorescence-positive intact cells
(IF technique) according to Fehm [8]. For the IC evalu-
ation, we followed the criteria proposed by Borgen, who
used the same antibody [18,19]. The criteria include
moderate to strong staining intensity for the entire cyto-
plasm in mononuclear cells lacking haematopoietic char-
acteristics [18,19]. The evaluation was performed by two
observers independently. All specimens were considered
either positive or negative when one or more CK-
positive cell was diagnosed. DTCs detected by IF are
illustrated in Figure 1 and by IC in Figure 2.
As a positive control for CK immunostaining, we
used the breast cancer cell line MCF7 spiked into blood
from healthy volunteers. The cell line was kindly pro-
vided by Prof. Stina Oredsson at Lund University. Theslides for negative controls were prepared in parallel
with those stained with anti-CK by omitting the pri-
mary antibody, and thus contained the same number of
cells (1.5 to 2 × 106). No positive results were observed
in the negative controls.
Bone marrow aspirates from 76 adult healthy bone
marrow donors were analysed separately.Statistical analysis
Distant disease-free survival (DDFS) and breast cancer-
specific survival (BCSS), measured from the month of
surgery to the last clinical follow-up or any breast
cancer-related event, were used as endpoints. DDFS
Falck et al. BMC Cancer 2012, 12:403 Page 5 of 9
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and liver.
Differences in the distribution of clinical data and
tumour characteristics between the DTC+ and DTC-
patients were evaluated using the X2 test. DDFS and BCSS
were estimated according to the Kaplan-Meier method,
and the log-rank test was used to compare survival in dif-
ferent subgroups. The Cox proportional hazards model
was fitted to explore the effects of tumour size, lymph
node status, ER and progesterone receptor content, age,
and NHG on BCSS and DDFS. Proportional hazards
assumptions were checked graphically.
P-values of <0.05 were considered statistically signifi-
cant. The statistical software package Stata 11.1 (Stata
Corp., College Station, TX, USA) was used for all statis-
tical calculations.Results
Detection of micrometastases
Analysis of DTCs was performed in 401 patients, and
CK-positive cells were found in 152 of these (38%). The
IF-based method resulted in 40% DTC-positive cases,
whereas 30% were positive using the IC method. How-
ever, there was no statistically significant difference be-
tween the detection rates of the two methods (p = 0.11).
The number of positive cells was not taken into account.Table 2 Patient`s and tumor characteristics in relation to pres
Characteristics Patients
analyzed by
IF
No DTC in
bone marrow N
(%)
DTC in
bone marrow
N (%)
p
Tumor size
≤ 20 mm 203 118 (58) 85 (42)
> 20 mm 123 78 (63) 45 (37)
Node status
N0 184 113 (61) 71 (39)
N+ 133 77 (58) 56 (42)
NHG
1 60 30 (50) 30 (50)
2 181 110 (61) 71 (39)
3 80 51 (64) 29 (36)
ER status
Positive 252 145 (58) 107 (42)
Negative 66 45 (68) 21 (32)
PR status
Positive 189 110 (58) 79 (42)
Negative 129 80 (62) 49 (38)
* X2-test for two categories and X2-test for trend for three ordered categories.
Abbreviations: IF= immunofluorescence, IC=immunocytochemistry, DTC= dissemina
histological grade, ER= oestrogen receptor, PR= progesterone receptor.Characteristics of DTCs and patients
Patient and tumour characteristics are listed in Table 1.
The relationship between DTC detection in bone mar-
row and clinicopathological variables in the study cohort
is presented in Table 2. There was no statistically signifi-
cant correlation between the presence of DTCs and the
characteristics, regardless of the method used for DTC
detection.
For survival analysis, we initially included all 401 patients
for whom DTC analysis was performed. In the cohort of
patients analysed with the IF staining procedure, the detec-
tion of DTCs in bone marrow was not related to either
DDFS (log-rank test, p= 0.60) (Figure 3) or BCSS (log-rank
test, p =0.37) (Figure 4). Stratifying the cohort according to
the method used for the detection of DTCs resulted in
similar results using Cox univariate analysis (Table 3). In
Cox univariate analysis of DDFS, the following clinico-
pathological variables were related to prognostic informa-
tion: lymph node metastases (+ vs. -: hazard ratio [HR],
5.5; 95% confidence interval [CI], 2.7–11), tumour size
(>20 vs. ≤20 mm: HR, 4.9; 95% CI, 2.6–9.4), NHG (3 vs. 1:
HR, 20; 95% CI, 2.7–147), ER (+ vs. -: HR, 0.39; 95% CI,
0.21–0.72), and PR, progesterone receptor (+ vs. -: HR,
0.43; 95% CI, 0.24–0.79). In a Cox proportional hazards
model for DDFS, lymph node metastases (+ vs. -: HR, 3.6;
95% CI, 1.7–7.4), tumour size (>20 vs. ≤20 mm: HR, 2.5;
95% CI, 1.1–5.1), and NHG (3 vs. 1: HR, 8.7; 95% CI,ence of DTC in bone marrow
-value*
Patients
analyzed by
IC
No DTC in
bone marrow
N (%)
DTC in
bone marrow
N (%)
p-value*
0.3 60 42 (70) 18 (30) 1.0
13 9 (69) 4 (31)
0.5 49 35 (71) 14 (29) 0.7
24 16 (67) 8 (33)
17 13 (76) 4 (24)
0.12 40 24 (60) 16 (40) 0.7
14 12 (86) 2 (14)
0.12 60 41 (68) 19 (32) 0.8
11 8 (73) 3 (27)
0.5 53 37 (70) 16 (30) 0.8
18 12 (67) 6 (33)
ted tumor cells, N0= node negative, N+=node positive, NHG= Nottingham
Figure 3 Distant disease-free survival (DDFS) in relation to
presence of DTC.
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The results for BCSS were similar (data not shown).
Subgroup analysis
When the cohort was stratified according to lymph node
status, Cox univariate analysis of N0 patients showed
that the presence of DTCs had no statistically significant
effect on prognosis in terms of DDFS (DTC+ vs. DTC-:
HR, 2.7; 95% CI, 0.72–9.1; p = 0.14). In the N+ group of
patients, the presence of DTCs had no significant effect
on DDFS (DTC+ vs. DTC-: HR, 0.84; 95% CI, 0.42–1.72;
p = 0.6). Although the presence of DTCs seemed to have
a more pronounced effect in the N0 subgroup, the inter-
action between lymph node status and the presence of
DTCs was not significant (p = 0.13). The results were
similar in the subgroups of patients in whom DTCs were
detected by IF and IC (data not shown).
The bone marrow from healthy adult bone marrow
donors was analysed using both methods. The analyses
were positive for epithelial cells in bone marrow in 19Figure 4 Breast cancer-specific survival (BCSS) in relation to
presence of DTC.(25%) samples, negative in 53 (70%), and inadequate or
ambiguous in 4 (5%).
Discussion
In the present study, the detection of DTCs in bone
marrow in female patients with primary breast cancer at
the time of diagnosis had no prognostic impact. Al-
though most publications report that detection of DTCs
in primary breast cancer is an independent prognostic
factor for recurrence and death, the clinical significance
of micrometastases in bone marrow remains controver-
sial. The American Society of Clinical Oncology did not
advocate it as a prognostic marker for clinical use be-
cause of insufficient data [16], and several concerns have
been raised regarding the standardisation of detection
using monoclonal antibodies against CKs. The standard-
isation of the detection method is based on IC using a
strict protocol for negative controls and morphological
evaluation of stained mononuclear cells. The present
study included patients before the standard protocol was
published [15], and the data are mainly derived from de-
tection by an IF staining procedure that was not
included in the published meta-analysis and is not advo-
cated by the consortium [7,15].
The detection of DTCs in bone marrow has been iden-
tified in several publications as an independent predictor
of poor outcome in patients with non-metastatic breast
cancer disease [14,20,21]. The level of evidence increased
when a pooled analysis of 4703 patients with breast can-
cer was published, assessing the poor prognostic signifi-
cance of the presence of DTCs in the bone marrow at
the 10-year follow-up [7]. The pooled analysis, which
included a large patient cohort, also enabled the analysis
of subgroups with statistical power. Interestingly, the lar-
gest difference in outcome for patients with DTC+ vs.
DTC- disease was in the subgroup in which all patients
received adjuvant systemic therapy. Although there was
a significantly higher risk of relapse in patients with
DTC+disease compared with patients with DTC- dis-
ease in the subset of patients who did not receive adju-
vant systemic therapy (n = 1036, 22%), the effect was
relatively small, but still significant (5-year follow-up: in-
cidence ratio, 2.0; 95% CI, 1.2–3.4). Aspects to consider
when estimating the results of these early reports are the
heterogeneity of the patients included and different
methods and techniques used to determine bone mar-
row dissemination. However, more recent studies per-
formed with standardised methods of detection also
propose a prognostic value of DTCs in bone marrow
[22-24]. Molloy et al. found clinical significance of DTCs
in bone marrow in terms of BCSS (HR, 2.1; p = 0.003),
but not in metastasis-free survival (HR, 1.5; p = 0.127)
[23]. Giluiano et al. reported that DTCs were present in
104/3413 (3.0%) patients and was associated with
Table 3 Cox univariate and multivariate analysis of
distant disease-free survival
Univariate analysis
(n ≤ 401)
Multivariate analysis
(n = 377)
Variable HR* 95% CI p-value HR** 95% CI p-value
DTC status
(IF and IC)
(n=401)
DTC+ vs DTC-
1.2 0.66-2.2 0.55
DTC status (IF)
(n=327)
1.2 0.63- 2.2 0.60
DTC+ vs DTC-
DTC statuc (IC)
(n=74)
DTC+ vs DTC-
0.84 0.09-8.1 0.88
Age 0.99 0.97-1.02 0.61
per year
Node status 5.5 2.7- 11 < 0.001 3.4 1.6- 7.2 0.001
N+ vs N0
Tumor size 4.9 2.6-9.4 < 0.001 2.5 1.2- 5.2 0.01
> 20 mm vs ≤
20 mm
NHG status 6.9 0.92-52 0.06 4.9 0.65-37 0.12
NHG 2 vs NHG 1
NHG 3 vs NHG 1 20 2.7- 147 0.004 8.7 1.1- 70 0.04
ER status 0.39 0.21-0.72 0.003 0.85 0.38- 1.9 0.7
ER+ vs ER-
PR status 0.43 0.24- 0.79 0.007 0.67 0.33- 1.4 0.3
PR+ vs PR-
* No significant deviations from proportional hazards (Schoenfeld’s test).
* *P=0.05 in Schoenfeld’s global six degree-of-freedom test of proportional
hazards.
Abbreviations: IF= immunofluorescence, IC=immunocytochemistry,
HR= hazard ratio, CI= confidence interval, DTC= disseminated tumor cells,
N0= node negative, N+= node positive, NHG= Nottingham histological grade,
ER= oestrogen receptor, PR= progesterone receptor.
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did not reach clinical validity in multivariate analysis.
They concluded that bone marrow aspiration was not
recommended in routine clinical practice for patients
with early breast cancer without an improved technique
for isolation and detection of occult tumour cells in
bone marrow [22]. Solá et al. found a higher frequency
of DTCs in a subgroup of patients who experienced
breast cancer-related events (13%), but the results did
not reach statistical significance because of low power
with few events [24]. Future studies will show whether
there is a predictive value in the choice of chemotherapy
regarding repeated sampling of DTCs during progression
of the disease. The persistent presence of DTCs during
follow-up was shown to be associated with a significantly
increased risk for relapse and death in breast cancer dis-
ease in a recently published pooled analysis [25].The biological tumour characteristics and the clinical
stage and follow-up data in the present study are in ac-
cordance with those of previous publications in the field
[8,9,11,12,26]. The presence of DTCs in 152 of 401 (38%)
patients in this study is in line with what previous authors
have reported, with a diagnostic rate of 20% to 40% re-
gardless of nodal status [7-9]. Although most authors
report a positive association with pathological stage and
tumour grade, other investigators have failed to detect any
correlation of DTCs with standard prognostic markers
[8,9,11,12,27]. The lack of correspondence between
accepted prognostic markers and the presence of DTCs in
bone marrow spans T1, T2, and T3 disease, and it shows
no correlation with nodal involvement [12].
The present study involved a prospective cohort of
women diagnosed with early breast cancer from the era
of screening mammography. This may have had an ef-
fect on the present cohort, which was weighted toward a
‘good’ prognostic profile with a favourable prognosis and
few events: small tumours (T1) in 66% of included
patients, N0 disease in 61%, and ER-positive tumours in
80%. However, the DTC detection rate is not necessarily
dependent on the clinical stage or tumour profile and is
still reported to be around 30% to 40% of included
patients in recently published studies [8,9,12]. Adjuvant
treatment with chemotherapy was given to only 65 of
401 patients. The subgroup analysis of N0 patients in
the present cohort gives the impression that DTCs may
be of some importance for these patients compared with
N+ patients. However, the few events reported to date
indicate that the study lacks the power to allow the de-
tection of any significant effect of DTCs in the N0 sub-
group. A longer follow-up period will be necessary to
fully elucidate this issue.
Standardisation of the detection of DTCs has been
widely discussed, and the main limitation of the present
study is that it was launched before a standardised
method was established. Using antibodies against differ-
ent CKs to detect epithelial cells in mesenchymal bone
marrow is considered to classify these cells as being of
tumour origin and thus micrometastases [28]. However,
conclusive studies comparing techniques and optimal
antibody dilution are not yet available from the same co-
hort of patients. In the present study, a switch was made
from analysing the samples with IF (n = 327) to IC
(n = 74), a method with growing acceptance at the time,
and with the use of published standards for handling of
the samples, enabling a more strict morphological evalu-
ation [18,19]. No differences were found between the
subset of patients analysed using the different methods
when comparing tumour and patient characteristics or
survival. Although there was no statistically significant
difference in detection rate, DTCs were diagnosed in
40% of the patients using the IF technique compared
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trols for all analysed samples irrespective of the method
used. Furthermore, we included bone marrow from 76
healthy adults, and the analyses were positive for epithe-
lial cells in the bone marrow of 19 (25%) of the samples.
This illustrates the lack of standardisation of the assays
used. Because CK-positive samples were found among
the healthy donors in the present study, we cannot ex-
clude the possibility that some of the DTC+ breast can-
cer patients were incorrectly classified. Although it was
not our initial intention, we also tested higher cut-offs
for defining DTC positivity without finding any associ-
ation with prognosis (data not shown).
Not all studies included in the meta-analysis reported
whether samples from healthy donors were analysed,
and in several of them, control samples were sparse
(<50 samples) [7]. Furthermore, false-positive controls
have been observed in the use of epithelial-specific mar-
kers (CKs), incorrectly classifying haematopoietic cells
(HCs) as tumour cells [18,29]. Epithelial-positive rates in
bone marrow have been reported in patients without
cancer, even after morphological criteria were applied
(5% and 30% in two different cohorts) [18,29]. However,
the findings in the present study, including 25% positive
cases among adult healthy bone marrow donors, raise
concerns about the specificity of the method used. One
possible mechanism for false-positive staining of HCs in
bone marrow is a direct reaction between specific HCs
and alkaline phosphatase (AP) [18] using the chromo-
genic visualisation technique. Staining bone marrow
with AP alone gave a strong positive reaction, and fur-
ther analysis identified these cells as possible plasma
cells/pre-B cells [18]. In addition, HCs can express CKs
illegitimately and thus stain with anti-CK, but strict
morphological evaluation often reveals the characteris-
tics of true DTCs [18]. Morphological evaluation of CK-
positive cells is thus crucial for the correct diagnosis of
DTCs, and in the present study, we applied the morpho-
logical criteria for diagnosis of DTCs analysed by IF and
IC [8,18].
A future topic of interest in the field of DTCs is the
investigation of the molecular characteristics in individ-
ual DTCs with the purpose of finding a marker to
monitor treatment susceptibility [8,30]. Molecular char-
acteristics are often diagnosed by the IF-based tech-
nique, which is less standardised than the preferred IC-
based method. Furthermore, molecular investigation of
matched pairs of primary tumours, metastasis, and
DTCs may give information about the progression of
cancer disease [28]. Of interest is that molecular sub-
classes of breast cancer tend to express different families
of CKs, which can be translated into different detection
rates throughout the molecular subclasses when only
one antibody against CKs is used [31]. Diagnosis ofDTCs during tumour progression must thus consider
using multiple antibodies against different CKs to cor-
rectly diagnose DTCs with a molecular profile other
than that of the primary tumour.Conclusions
The present study did not confirm the results of previ-
ous publications that suggested that DTCs in bone mar-
row are an independent prognostic marker of poor
prognosis in primary breast cancer. A more standardised
detection method of DTC in bone marrow has been pro-
posed since the start of the present study. The invasive
nature of the diagnostic procedure of DTCs and tech-
nical challenges linked to the method makes the tech-
nique unsuitable for inclusion in the standard care of
primary breast cancer.
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